论文部分内容阅读
[目的]探讨进展期胃癌术后早期腹腔温热灌注化疗对于改善患者生存率的意义。[方法]159例T3、T4(Ⅱ～Ⅳ期)胃癌手术患者,对比研究腹腔温热化疗组化疗方案(78例)与对照组(81例)术后并发症、复发转移率和3年生存率。[结果]并发症比较:腹腔温热化疗组腹胀及肌酐升高的发生率均显著高于对照组(92.3%vs.14.8%,P<0.05;11.5%vs.1.2%,P<0.05),但治疗后均恢复正常。术后复发转移:腹腔温热化疗组腹膜腔复发转移率显著低于对照组(32.1%vs.54.3%,P<0.05)。腹腔温热化疗组3年生存率显著高于对照组(52.6%vs.32.1%,P=0.003)。[结论]进展期胃癌术后早期进行腹腔温热灌注化疗能够减少腹膜腔复发转移,提高生存率。
[Objective] To investigate the significance of early postoperative peritoneal hyperthermic perfusion chemotherapy for improving the survival rate of patients with advanced gastric cancer. [Method] One hundred and ninety-nine patients with T3 and T4 gastric cancer were divided into two groups: the control group (78 cases) and the control group (81 cases) with postoperative complications, recurrence and metastasis rate and 3-year survival rate rate. [Results] Complications: The incidences of abdominal distension and creatinine were significantly higher in the group with abdominal thermochemotherapy than those in the control group (92.3% vs.14.8%, P <0.05; 11.5% vs.1.2%, P <0.05) But returned to normal after treatment. Postoperative recurrence and metastasis: The rate of peritoneal cavity recurrence and metastasis was significantly lower in the celiac group than in the control group (32.1% vs.54.3%, P <0.05). The 3-year survival rate of the celiac thermochemotherapy group was significantly higher than that of the control group (52.6% vs.32.1%, P = 0.003). [Conclusion] The early peritoneal hyperthermic perfusion chemotherapy in advanced gastric cancer can reduce the recurrence and metastasis of peritoneal cavity and increase the survival rate.